SCHEMBL665288

SCHEMBL665288

O=C(NC1=CC(=O)C2OC2C1O)c1cccc(Cl)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.53
P2RX1 P51575 2/20 0.45
P2RX4 Q99571 1/20 0.45
P2RX7 Q99572 1/20 0.45
TMPRSS4 Q9NRS4 1/20 0.45
KLKB1 P03952 1/20 0.45
PLAU P00749 2/20 0.43
PLAT P00750 2/20 0.43
F2 P00734 1/20 0.43
F10 P00742 1/20 0.43
ALOX15 P16050 1/20 0.40
TAS1R3 Q7RTX0 6/20 0.40
TAS1R1 Q7RTX1 6/20 0.40
TAS1R2 Q8TE23 6/20 0.40
KDR P35968 1/20 0.40
KLK1 P06870 1/20 0.38
KLK5 Q9Y337 1/20 0.38
CYP1A2 P05177 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL115782 0.85 PARK7 (0.51) PARK7P2RX1PLAUPLATF2
SCHEMBL663095 0.84 PARK7 (0.44) PARK7
Dehydroxymethylepoxyquinomicin SCHEMBL1669417 0.82 PARK7 (0.54) PARK7P2RX1P2RX4P2RX7HPGD
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.82 PARK7 (0.54) PARK7P2RX1P2RX4P2RX7HPGD
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.82 PARK7 (0.54) PARK7P2RX1P2RX4P2RX7HPGD
Dehydroxymethylepoxyquinomicin SCHEMBL14504317 0.82 PARK7 (0.54) PARK7P2RX1P2RX4P2RX7HPGD
SCHEMBL665474 0.81 PARK7 (0.49) PARK7P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL665039 0.80 PARK7 (0.50) PARK7P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL666185 0.80 P2RX1 (0.51) PARK7P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL665471 0.79 PARK7 (0.57) PARK7P2RX1P2RX4P2RX7ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) PROFECTUS BIOSCIENCES, INC. (US) 2012-02-23 US claimed
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) PROFECTUS BIOSCIENCES, INC. (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) NFKBIA, IKBKB, NFKB1 PARK7 3384/4885P2RX1 855/4885P2RX4 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.